Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGEING feasibility study of Envarsus versus twice-daily tacrolimus after kidney transplantation
2018-003254-24Phase 4Unknown
- Sponsor
- University Hospitals Birmingham
- Start
- Jun 2019
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tacrolimus in kidney transplant and kidney allograft rejection (2 arms), sponsored by University Hospitals Birmingham. Primary endpoint: Feasibility of using Envarsus versus twice-daily tacrolimus in older kidney transplant recipients. Status: unknown.
02
Drugs
tacrolimus
03
Conditions
kidney transplantkidney allograft rejection
Beyond the preview
Go deeper on 2018-003254-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003254-24.